drugset / Trial / NCT06360081
A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers
RandomizedCrossoverOpen-labelTreatment
Summary
The main objective of this trial is to establish the bioequivalence of zongertinib tablet from manufacturer 1 (Test, T) compared with zongertinib tablet from manufacturer 2 (reference, R) following oral administration.
Timeline
- Start
- 2024-04-30
- Primary completion
- 2024-06-30
- Completion
- 2024-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zongertinib | Small molecule | 60 mg | Oral |
Indications
No indication recorded.